Starting heart failure medications with Impella 5.5 for recovery
Part of Heart & circulation clinical trials.
This trial tests if starting and adjusting heart failure medications with the help of an Impella 5.5 heart pump can improve recovery for people in cardiogenic shock. It focuses on those who are not on enough guideline-directed medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 79 years old.
- Your heart's pumping ability (LVEF) is 40% or less.
- You are in cardiogenic shock (very low blood pressure or needing support).
- You are on 2 or fewer types of heart failure medications, or your doses are low.
- You do not have conditions like certain heart blockages, allergies to these drugs, or other serious illnesses listed in the exclusion criteria.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether doctors can safely reduce heart and blood-pressure support sooner in people with severe heart failure “shock.” It may help avoid side effects of strong medicines/devices while keeping the body’s organs well supported.
This study tests whether using a temporary heart pump called Impella 5.5 can help strengthen a very weak and enlarged heart (dilated cardiomyopathy) in people who are waiting for a heart transplant. If you qualify, the pump is placed to support your heart temporarily, and the research team will check how your heart responds.
This trial studies whether putting in a small heart pump early (through the leg) helps people with a heart attack complicated by severe heart weakness (“cardiogenic shock”) compared with standard treatment. It aims to improve survival and recovery by supporting blood flow sooner.
This trial tests a new heart pump (Impella device) for people who have a severe heart attack and go into shock (very low blood pressure). It aims to see if the pump can help the heart recover better than standard care.
This study reviews how well people tolerated the Impella heart pump during cardiogenic shock and what complications occurred. It looks at past cases from 2010 to 2022 to help doctors understand the safety of this device.
This study examines detailed data from patients who received an Impella 5.5 heart pump to treat cardiogenic shock—a life-threatening condition where the heart cannot pump enough blood. Researchers use advanced computer analysis to understand what helps patients recover best.
Hear when a new Heart failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.